Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

The American Cancer Society estimates 236,740 new cases of lung cancer and 130,180 deaths from lung cancer in 2022, second only to prostate cancer in men and breast cancer in women.1

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

Amanda L. Brink, DNP, APRN, FNP-BC, AOCNP Advanced Practice Registered Nurse Department of Investigational Cancer Therapeutics Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston, TX Aung Naing, MD, FACP Professor Department of Investigational Cancer Therapeutics Division of Cancer Medicine University of Texas MD Anderson Cancer Center [ Read More ]